Guidance | Notifying FDA of a Permanent Discontinuance or Interruption in Manufacturing Under Section 506C of the FD&C Act

The guidance is intended to help applicants and manufacturers provide the agency with timely and informative notifications about changes in the production of certain drugs and biological products.